Lupin launches authorized generic of Vimovo

Patients with arthritis have a new generic treatment available that also helps decrease the risk of developing gastric ulcers. Lupin is introducing an authorized generic of Horizon Therapeutics’ Vimovo (naproxen/esomeprazole magnesium) delayed-release tablets, in dosage strengths of 375 mg/20 mg and 500 mg/20 mg.

The product is a combination of naproxen, a non-steroidal anti-inflammatory drug, and esomeprazole magnesium, a proton pump inhibitor indicated in adult and adolescent patients 12 years of age and older weighing at least 38 kg, requiring naproxen for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers.

Naproxen and esomeprazole magnesium delayed-release tablets had a market value of approximately $400 million, according to IQVIA January 2020 data.